-
-
-
-
-
-
-
Bristol-Myers Squibb (BMY) Tops Q2 EPS by 43c, Beats on Revenue; Offers FY26 Guidance
-
-
-
-
-
-
-
Bristol Myers Squibb drug shows survival benefit in cancer trials
-
-
-
-
-
-
-
Bristol Myers Squibb Announces CELMoD Mezigdomide Reduces Risk of Disease Progression or Death by More than 50% vs. Standard of Care in Relapsed or Refractory Multiple Myeloma
-
-
-
-
-
-
-
Bristol-Myers Squibb trumps Q1 estimates, maintains full-year outlook
-
-
-
-
-
-
-
Bristol Myers Squibb study shows stable symptom transition to COBENFY
-
-
-
-
-
-
-
Bristol Myers Squibb to Report Results for First Quarter 2026 on April 30, 2026
-
-
-
-
-
-
-
Bristol-Myers Squibb Co. (BMY) PT Raised to $75 at Piper Sandler
-
1,217,581 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

